MCID: MMB011
MIFTS: 50

Membranous Nephropathy

Categories: Rare diseases, Nephrological diseases

Aliases & Classifications for Membranous Nephropathy

MalaCards integrated aliases for Membranous Nephropathy:

Name: Membranous Nephropathy 54 12 50 29
Membranous Glomerulonephritis 12 50 14 69
Idiopathic Membranous Glomerulonephritis 56 69
Idiopathic Membranous Nephropathy 50 52
Glomerulonephritis, Membranous 50 42
Membranous Nephropathy, Susceptibility to 13
Extramembranous Glomerulonephritis 50
Nephropathy Membranous 52
Membranous Gn 50
Mgn 50

Classifications:

Orphanet: 56  
Rare renal diseases


External Ids:

OMIM 54 614692
Disease Ontology 12 DOID:10976
ICD10 33 N03.2
MeSH 42 D015433
NCIt 47 C34645
SNOMED-CT 64 197710000 77182004
Orphanet 56 ORPHA97560
UMLS via Orphanet 70 C0086445
ICD10 via Orphanet 34 N04.2
UMLS 69 C0017665

Summaries for Membranous Nephropathy

OMIM : 54
Membranous nephropathy, a major cause of the nephrotic syndrome in adults, is characterized by the presence of glomerular deposits that typically contain immunoglobulin and complement components. Two major antigens, both of which are membrane glycoproteins, have been identified in human membranous nephropathy. Neutral endopeptidase (MME; 120520) is the alloantigen involved in membranous nephropathy in neonates whose mothers have a deficiency of this enzyme. The second is the M-type phospholipase A2 receptor (PLA2R1; 604939), the first antigen identified in adults with idiopathic membranous nephropathy, which is generally considered to be an autoimmune disease. In addition, autoantibodies against aldose reductase (AKR1B1; 103880), mitochondrial superoxide dismutase-2 (SOD2; 147460), and THSD7A (612249) have been found in serum and glomeruli from patients with idiopathic membranous nephropathy. Familial occurrence has been noted by Short et al. (1984) and Bockenhauer et al. (2008) (summary by Stanescu et al., 2011 and Tomas et al., 2014). (614692)

MalaCards based summary : Membranous Nephropathy, also known as membranous glomerulonephritis, is related to lymphoma and alport syndrome and thin basement membrane nephropathy. An important gene associated with Membranous Nephropathy is MBNP (?Membranous Nephropathy, Susceptibility To), and among its related pathways/superpathways are Phagosome and Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Acetylcysteine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and heart, and related phenotypes are homeostasis/metabolism and renal/urinary system

NIH Rare Diseases : 50 membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. when the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood pressure. in many cases, the underlying cause of membranous nephropathy is not known. some cases are associated with other conditions (lupus), infections (hepatitis b and c), cancer or as a side effect of certain medications. the goal of treatment is to reduce symptoms and slow the progression of the disease.  last updated: 9/2/2014

Wikipedia : 72 Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly... more...

Related Diseases for Membranous Nephropathy

Diseases in the Membranous Nephropathy family:

Congenital Membranous Nephropathy Due to Maternal Anti-Neutral Endopeptidase Alloimmunization

Diseases related to Membranous Nephropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
id Related Disease Score Top Affiliating Genes
1 lymphoma 29.6 ACE ALB CD79A
2 alport syndrome and thin basement membrane nephropathy 12.1
3 anti-basement membrane glomerulonephritis 12.0
4 congenital membranous nephropathy due to maternal anti-neutral endopeptidase alloimmunization 11.9
5 hematuria, benign familial 11.2
6 renal hypoplasia 10.7 NPHS1 NPHS2
7 monostotic fibrous dysplasia 10.7 CD2AP NPHS2
8 46xy sex reversal 8 10.6 NPHS1 NPHS2
9 retinitis pigmentosa 70 10.5 ACE ALB
10 sarcocystosis 10.5 ALB NPHS1 NPHS2
11 cardiomyopathy, dilated, 1ee 10.4 CD2AP NPHS1 NPHS2
12 congenital pulmonary alveolar proteinosis 10.4 CD2AP NPHS1 NPHS2
13 female stress incontinence 10.4 CD2AP NPHS1 NPHS2
14 hyperferritinemia-cataract syndrome 10.4 CD2AP NPHS1 NPHS2
15 nephrotic syndrome, type 4 10.4 CD2AP NPHS1 NPHS2
16 meacham syndrome 10.4 CD2AP NPHS1 NPHS2
17 atopic dermatitis 5 10.4 ALB CD79A
18 microinvasive cervical squamous cell carcinoma 10.3 ALB CD79A
19 ovary transitional cell carcinoma 10.3 ALB CD79A
20 retinitis pigmentosa 17 10.3 ACE ALB NPHS1
21 infertility due to extratesticular cause 10.3 ALB CD79A
22 male genital organ stricture 10.3 ALB CD79A
23 adie pupil 10.3 ALB CD79A
24 pedophilia 10.2 CD79A HLA-DQA1
25 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.2 ALB CD79A
26 atrophic vulva 10.2 ALB C3
27 immune-complex glomerulonephritis 10.2 ALB CD79A
28 folliculitis 10.2 ALB C3
29 tarp syndrome 10.2 ALB CD79A
30 nephrotic syndrome 10.2
31 synovial chondromatosis 10.2 ACE ALB
32 hyperbiliverdinemia 10.2 CD2AP NPHS1 NPHS2
33 glomerulonephritis 10.1
34 transient refractive change 10.1 ALB CD2AP NPHS1 NPHS2
35 chronic mucocutaneous candidiasis 10.1 C3 CD79A
36 adrenal gland disease 10.1 ALB CD79A
37 vaginal endometrial stromal sarcoma 10.1 C3 CD79A
38 alport syndrome 10.1
39 hepatitis 10.1
40 hepatitis b 10.0
41 partial circumpapillary choroid dystrophy 10.0 C3 CD79A
42 interstitial nephritis 10.0
43 focal segmental glomerulosclerosis 10.0
44 pyrimidine metabolic disorder 10.0 ALB CD79A
45 acute chest syndrome 9.9 ACE ALB CD79A
46 dermatomycosis 9.9 ALB C3 CD79A
47 lacrimal system cancer 9.9 ACE ALB CD79A
48 crescentic glomerulonephritis 9.9
49 adenocarcinoma 9.9 ACE ALB
50 acute gonococcal cervicitis 9.9 ALB CD79A

Graphical network of the top 20 diseases related to Membranous Nephropathy:



Diseases related to Membranous Nephropathy

Symptoms & Phenotypes for Membranous Nephropathy

Clinical features from OMIM:

614692

MGI Mouse Phenotypes related to Membranous Nephropathy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.7 ACE ALB C3 CD2AP CD79A LRP2
2 renal/urinary system MP:0005367 9.28 ACE ALB C3 CD2AP CD79A LRP2

Drugs & Therapeutics for Membranous Nephropathy

Drugs for Membranous Nephropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
5
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104987-11-3 445643 439492
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
8
Pravastatin Approved Phase 4 81093-37-0 54687
9
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
10
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
11
Angiotensin II Investigational Phase 4,Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
12 Antidotes Phase 4
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2
14 Antioxidants Phase 4,Phase 2
15 Antiviral Agents Phase 4,Phase 1,Phase 2
16 Expectorants Phase 4
17 N-monoacetylcystine Phase 4
18 Protective Agents Phase 4,Phase 2,Phase 3
19 Respiratory System Agents Phase 4
20 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
21 Hormones Phase 4,Phase 2,Phase 3,Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
24 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
25 Antifungal Agents Phase 4,Phase 3,Phase 2
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Cyclosporins Phase 4,Phase 3,Phase 2
29 Dermatologic Agents Phase 4,Phase 3,Phase 2
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
32 Angiotensin II Type 1 Receptor Blockers Phase 4
33 Angiotensin Receptor Antagonists Phase 4,Phase 3
34 Angiotensinogen Phase 4,Phase 3
35 Antihypertensive Agents Phase 4
36 Adrenocorticotropic Hormone Phase 4,Phase 2,Phase 1
37 beta-endorphin Phase 4,Phase 2,Phase 1
38 Melanocyte-Stimulating Hormones Phase 4,Phase 2,Phase 1
39 Immunoglobulin A Phase 4,Phase 2
40 Antimetabolites Phase 4,Phase 3,Phase 2
41 Endorphins Phase 4
42 Neurotransmitter Agents Phase 4,Phase 3
43 Anticholesteremic Agents Phase 4,Phase 3
44 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3
45 Hypolipidemic Agents Phase 4,Phase 3
46 Lipid Regulating Agents Phase 4,Phase 3
47 Atorvastatin Calcium Phase 4 134523-03-8
48 Calcium, Dietary Phase 4,Phase 3
49 Cholagogues and Choleretics Phase 4
50 Tripterygium Nutraceutical Phase 4

Interventional clinical trials:

(show top 50) (show all 87)

id Name Status NCT ID Phase Drugs
1 Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients Unknown status NCT01111422 Phase 4 N-acetylcysteine
2 To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Completed NCT00518219 Phase 4 TW
3 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
4 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
5 Adrenocorticotropic Hormone in Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
6 Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
7 Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
8 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
9 Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Recruiting NCT02992548 Phase 4 Pravastatin
10 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Active, not recruiting NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
11 Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Active, not recruiting NCT02863185 Phase 4 Pitavastatin;Atorvastatin
12 Acthar for Treatment of Post-transplant FSGS Not yet recruiting NCT02399462 Phase 4 Acthar
13 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Not yet recruiting NCT02338635 Phase 4 Ursodeoxycholic Acid
14 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
15 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
16 Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease Unknown status NCT01103076 Phase 2, Phase 3
17 High Flux Hemodialysis Thrice Versus Once Unknown status NCT00714662 Phase 3
18 Rituximab in Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
19 Mycophenolate Mofetil in Membranous Nephropathy Completed NCT00135967 Phase 2, Phase 3 mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9
20 Treatment of Patients With Idiopathic Membranous Nephropathy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
21 Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
22 Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
23 A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis Completed NCT00404794 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and tacrolimus
24 Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy Recruiting NCT01955187 Phase 3 TACROLIMUS;RITUXIMAB;METHYLPREDNISOLONE;CYCLOPHOSPHAMIDE
25 Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
26 Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy Active, not recruiting NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
27 MEmbranous Nephropathy Trial Of Rituximab Active, not recruiting NCT01180036 Phase 2, Phase 3 Rituximab;Cyclosporine
28 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Active, not recruiting NCT02077868 Phase 3 MGN1703 treatment
29 Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy Active, not recruiting NCT01208818 Phase 3 Cyclophosphamide + Bortezomib + Dexamethasone regimen;Bortezomib +Dexamethasone regimen
30 A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy Unknown status NCT02173106 Phase 2 steroid & Cyclosporin
31 Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy Completed NCT00694863 Phase 2 tetracosactide hexacetaat
32 Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy Completed NCT00050713 Phase 2 Sirolimus
33 Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma Completed NCT01208194 Phase 2 MGN1703;Placebo
34 A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Completed NCT01093157 Phase 1, Phase 2 Adrenocorticotrophic hormone ACTH
35 Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection Completed NCT02443935 Phase 1, Phase 2 MGN1703;MGN1703
36 Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV Completed NCT02690103 Phase 2 pegylated IFN;Ribavirin
37 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Completed NCT01610492 Phase 2 belimumab
38 Drug Therapy in Lupus Nephropathy Completed NCT00001212 Phase 2 prednisone;cyclophosphamide;cyclosporin A
39 Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients Completed NCT00687258 Phase 2
40 Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy Completed NCT01003236 Phase 2 placebo;Milk Thistle extract
41 Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy Recruiting NCT03255447 Phase 2
42 Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN) Recruiting NCT03285711 Phase 2 Filgotinib;GS-9876;Filgotinib placebo;GS-9876 placebo
43 Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy Recruiting NCT00977977 Phase 2 Rituximab Infusion;Oral Cyclosporine
44 Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Recruiting NCT02682407 Phase 2
45 Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC Active, not recruiting NCT02200081 Phase 2 MGN1703
46 A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) Active, not recruiting NCT01265368 Phase 1, Phase 2
47 Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Withdrawn NCT01762852 Phase 2 Belimumab 10 mg;Placebo
48 A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703 Completed NCT01982747 Phase 1 MGN-Placebo;Placebo-MGN
49 Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy Completed NCT00805753 Phase 1 ACTH
50 Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis Completed NCT01207297 Phase 1 Tacrolimus;cyclophosphamide

Search NIH Clinical Center for Membranous Nephropathy

Cochrane evidence based reviews: glomerulonephritis, membranous

Genetic Tests for Membranous Nephropathy

Genetic tests related to Membranous Nephropathy:

id Genetic test Affiliating Genes
1 Membranous Nephropathy 29

Anatomical Context for Membranous Nephropathy

MalaCards organs/tissues related to Membranous Nephropathy:

39
Kidney, Bone, Heart, Neutrophil, Endothelial, T Cells, Bone Marrow

Publications for Membranous Nephropathy

Articles related to Membranous Nephropathy:

(show top 50) (show all 355)
id Title Authors Year
1
Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy. ( 28849274 )
2017
2
Clinicopathological and long-term prognostic features of membranous nephropathy with crescents: a Japanese single-center experience. ( 28852884 )
2017
3
Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study. ( 28614271 )
2017
4
A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. ( 28814510 )
2017
5
Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy. ( 28904948 )
2017
6
Blockage of the lysosome-dependent autophagic pathway contributes to complement membrane attack complex-induced podocyte injury in idiopathic membranous nephropathy. ( 28819100 )
2017
7
Ultrasensitive Quantitation of Anti-Phospholipase A2 Receptor Antibody as A Diagnostic and Prognostic Indicator of Idiopathic Membranous Nephropathy. ( 28935926 )
2017
8
Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. ( 28821362 )
2017
9
Continuing the paradigm shift in the treatment of idiopathic membranous nephropathy. ( 28944778 )
2017
10
Pulmonary thromboembolism as first presentation of childhood membranous nephropathy. ( 28937086 )
2017
11
Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy. ( 28904360 )
2017
12
A Case of the nephrotic syndrome in bone marrow transplantation recipient, histologically showing overlapped glomerular lesions of thrombotic microangiopathy and membranous nephropathy. ( 28940837 )
2017
13
A comprehensive narrative review of diagnostic biomarkers in human primary membranous nephropathy. ( 28891307 )
2017
14
Female Patient with Alport Syndrome and Concomitant Membranous Nephropathy: Susceptibility or Association of Two Diseases? ( 28245485 )
2017
15
Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents. ( 28877834 )
2017
16
Circulating antibodies to I+-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy. ( 26830547 )
2017
17
Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. ( 28056860 )
2017
18
Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy. ( 28852480 )
2017
19
Risk alleles for IgA nephropathy-associated SNPs conferred completely opposite effects to idiopathic membranous nephropathy in Chinese Han. ( 28929317 )
2017
20
Utility of Determining Autoantibodies to M-type Phospholipase A2 Receptor in Diagnosing Primary Membranous Nephropathy: An Ideal Setting. ( 28904444 )
2017
21
Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. ( 28882100 )
2017
22
Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. ( 28898290 )
2017
23
Treatment of primary membranous nephropathy: where are we now? ( 28875476 )
2017
24
Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. ( 28257452 )
2017
25
Membranous nephropathy: integrating basic science into improved clinical management. ( 28065518 )
2017
26
Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome. ( 28090051 )
2017
27
Translational Aspects of Primary Membranous Nephropathy. ( 28863791 )
2017
28
Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis. ( 28084563 )
2017
29
HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy. ( 27631233 )
2016
30
Membranous Nephropathy with an Enhanced Granular Expression of Thrombospondin Type-1 Domain-containing 7A in a Pregnant Woman. ( 27629964 )
2016
31
Detection and Clinical Significance of Glomerular M-type Phospholipase A2 Receptor in Patients with Idiopathic Membranous Nephropathy. ( 27554390 )
2016
32
Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as prognostic markers in idiopathic membranous nephropathy. ( 25762211 )
2016
33
Alteration of histone H3K4 methylation in glomerular podocytes associated with proteinuria in patients with membranous nephropathy. ( 27855638 )
2016
34
Treatment with rituximab in idiopathic membranous nephropathy. ( 27994855 )
2016
35
Clinical Predictors of Response to Prednisone Plus Cyclophosphamide in Patients with Idiopathic Membranous Nephropathy. ( 27974710 )
2016
36
Necrotizing and crescentic glomerulonephritis with membranous nephropathy in a patient exposed to levamisole-adulterated cocaine. ( 26985374 )
2016
37
Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab. ( 27942609 )
2016
38
Biomarkers to detect membranous nephropathy in Chinese patients. ( 27634909 )
2016
39
Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: a retrospective analysis of 9 cases. ( 27624606 )
2016
40
PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy. ( 27876003 )
2016
41
Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. ( 27783276 )
2016
42
Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China. ( 27365535 )
2016
43
Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy? ( 27083274 )
2016
44
Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy. ( 27199983 )
2016
45
PLA2R and membranous nephropathy: A 3a88year prospective Australian study. ( 26369693 )
2016
46
Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. ( 26854647 )
2016
47
First report of membranous nephropathy and systemic lupus erythematosus associated with abatacept in rheumatoid arthritis. ( 27462998 )
2016
48
Membranous Nephropathy in the Kidney Allograft. ( 27646575 )
2016
49
Course of membranous nephropathy during multiple gestations. ( 27903580 )
2016
50
Remarks about the study of an unusual presentation of venous thrombosis in a child with idiopathic membranous nephropathy. ( 27215268 )
2016

Variations for Membranous Nephropathy

Expression for Membranous Nephropathy

Search GEO for disease gene expression data for Membranous Nephropathy.

Pathways for Membranous Nephropathy

Pathways related to Membranous Nephropathy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.68 C3 HLA-DQA1 PLA2R1
2 10.89 CD2AP MME NPHS1 NPHS2 VTN
3 10.67 ACE MME
4 10.55 CD2AP NPHS1 NPHS2
5 10.5 CD2AP NPHS1

GO Terms for Membranous Nephropathy

Cellular components related to Membranous Nephropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.93 ACE C3 CD2AP CD79A HLA-DQA1 LRP2
2 extracellular region GO:0005576 9.92 ACE ALB C3 LRPAP1 PLA2R1 THSD7A
3 endoplasmic reticulum GO:0005783 9.88 ALB HLA-DQA1 LRP2 LRPAP1 NPHS2 VTN
4 lysosome GO:0005764 9.67 ACE HLA-DQA1 LRP2 TINAG
5 extracellular exosome GO:0070062 9.36 ACE ALB C3 CD2AP LRP2 MME
6 slit diaphragm GO:0036057 9.26 NPHS1 NPHS2
7 rough endoplasmic reticulum lumen GO:0048237 8.96 LRPAP1 VTN

Biological processes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-amyloid metabolic process GO:0050435 9.32 ACE MME
2 angiotensin maturation GO:0002003 9.26 ACE MME
3 replicative senescence GO:0090399 9.16 MME PLA2R1
4 receptor-mediated endocytosis GO:0006898 9.02 ALB LRP2 PLA2R1 TINAG VTN
5 regulation of receptor-mediated endocytosis GO:0048259 8.96 CD2AP LRPAP1

Molecular functions related to Membranous Nephropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 polysaccharide binding GO:0030247 9.16 TINAG VTN
2 drug binding GO:0008144 8.96 ACE ALB
3 exopeptidase activity GO:0008238 8.62 ACE MME

Sources for Membranous Nephropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....